Nicardipine hydrochloride, 2-(N-benzyl-N-methyl amino) ethyl methyl 1, 4-dihydro- 2, 6-dimethyl-4-(m-nitro phenyl)-3, 5-pyridinedicarboxylate mono hydrochloride, is a calcium antagonist with highly potent vasodilating activity and has been widely used for the treatment of hypertension and cardiovascular disease. Nicardipine hydrochloride is the hydrochloride salt preparation of Nicardipine and a potent L-type calcium channel protein inhibitor. Nicardipine is described to alter cytochrome P-450 3A expression through induction of CYP3A. Nicardipine blockade of Ca2+ channels has been correlated to antihypertensive effects. It belongs to a class II drug in BCS classification i.e. low solubility and high permeability. One of the major problems with this drug is its low solubility in biological fluids which results into poor bioavailability after oral administration to improve the aqueous solubility and dissolution rate of the Nicardipine solid dispersions of drug using different methods were prepared and investigated. Enhancement of solubility of Nicardipine was observed with solid dispersion of drug using carriers such as [(NC: HPβCD): GMS: PEG4000] by fusion method. The observed results showed the solid dispersion of drug greater than the pure drug.